

Allergy Immunotherapy Market Set for 40% Growth, Attracting Manufacturers with Proactive Solutions

*Allergy Immunotherapy Market
forecasted for 40% growth by 2035,*

driven by solutions addressing manufacturers' key challenges and supporting future growth.

NEW YORK, DE, UNITED STATES, August 7, 2025 /EINPresswire.com/ -- The [Allergy](#)

“

The Allergy Immunotherapy Market is ripe with opportunity for manufacturers ready to solve critical public health challenges.”

Sabyasachi Ghosh

[Immunotherapy Market](#) is poised for a significant expansion, with a forecasted growth of 40% over the next decade. Projected to climb from a valuation of USD 99.7 million in 2025 to USD 249.3 million by 2035, this market represents a compelling opportunity for manufacturers seeking to address a critical, unmet need in global health. The market's rapid expansion, marked by a compound annual growth rate (CAGR) of 8.1%, signals a clear shift from traditional avoidance strategies to proactive, disease-modifying treatments. For manufacturers, this trend

presents a clear pathway to create solutions that not only meet patient demand but also integrate seamlessly into evolving clinical ecosystems.


The market's growth is a direct response to a rising public health challenge: the increasing prevalence of food allergies, particularly among children. Current treatment paradigms of strict avoidance and emergency interventions like epinephrine fall short of providing a long-term, sustainable solution. This is where immunotherapy, with its ability to desensitize patients to allergenic proteins, offers a revolutionary, proactive approach. Manufacturers can seize this opportunity by developing therapies that empower patients with dietary freedom and reduce the constant anxiety associated with accidental exposure.

Accelerated Adoption in the Next Five Years

The period from 2025 to 2030 is projected to be a phase of accelerated adoption, with the market value increasing by nearly USD 57.9 million. This initial surge will be fueled by heightened societal awareness, evolving regulatory frameworks, and a growing body of real-world success stories. Early adopters, including allergists and specialty clinics, are already integrating oral

immunotherapy (OIT) and biologic therapies into mainstream treatment pathways. During this time, PALFORZIA, an oral immunotherapy product, is expected to maintain a dominant position with over an 80% revenue share, a testament to the strong demand for proven solutions that offer relief and peace of mind to families.

This era is characterized by the establishment of foundational therapies and a maturing clinical landscape. For manufacturers, the key to success lies in understanding and capitalizing on this momentum. Developing complementary solutions, such as digital tools for adherence or telehealth platforms for monitoring, can provide a competitive edge. This is a market that rewards innovation that extends beyond the therapeutic product itself, focusing on enhancing the entire patient and provider experience.



Innovation and Integration Drive Second Half of Decade

The momentum will continue to build from 2030 to 2035, with the market adding another USD 91.6 million. This second phase will be defined by technological advancements, greater clinical integration, and rising patient empowerment. New entrants and emerging solutions will gain traction, building upon the foundation laid by the first wave of approved products. This period will also see the revenue share of XOLAIR (omalizumab), a biologic-based adjunct therapy, grow to approximately 22% by the end of the decade. This indicates a growing trend toward more complex, multi-faceted treatment approaches, reflecting the need for personalized care models and advanced diagnostics.

For manufacturers, the focus will shift from product introduction to market diversification and integration. Success will depend on the ability to develop solutions that are not only therapeutically effective but also seamlessly integrate into broader patient management frameworks. This includes leveraging real-world data analytics, automated dosing support, and coordinated care pathways. Competitive differentiation will be increasingly reliant on a manufacturer's ability to offer a holistic solution that improves treatment precision, patient engagement, and clinical outcomes across diverse demographics.

Regional Growth Highlights

The Allergy Immunotherapy Market's growth is global, but its adoption varies significantly by region. Europe is projected to lead with a CAGR of 9.1%, with Germany, France, and the UK at the forefront. The United States, with a forecasted 7.5% CAGR, remains a powerhouse, driven by early regulatory approval of products like PALFORZIA and strong parental demand. In Asia, emerging markets like China, India, and South Korea, while in earlier stages of development, are showing promising growth trajectories as urban healthcare infrastructure expands and awareness rises. For manufacturers, this regional variability offers a strategic opportunity to tailor market entry and product development to specific regulatory environments, clinical practices, and patient needs.

In the United States, robust reimbursement policies and a strong network of specialty clinics are facilitating rapid clinical adoption. In Europe, countries like the UK and Germany are prioritizing real-world data collection and integrating OIT pilot programs into their national healthcare systems. Meanwhile, in Asia, growth is being driven by academic-led research and a digitally integrated healthcare infrastructure that supports innovative solutions. Manufacturers can leverage these distinct regional dynamics to build targeted and effective commercialization strategies.

Request Allergy Immunotherapy Market Draft Report:

<https://www.futuremarketinsights.com/reports/sample/rep-gb-9043>

For more on their methodology and market coverage, visit

<https://www.futuremarketinsights.com/about-us>

The Competitive Landscape and Future Outlook

The market is currently dominated by a few key players, with Stallergenes Greer holding a commanding lead due to its successful product, PALFORZIA. This product has not only validated the clinical pathway for OIT but also set a benchmark for future product development. However, the landscape is evolving, with companies like Genentech strategically positioning themselves with biologic-based adjuncts, aiming to enhance the safety and efficacy of immunotherapy protocols.

Editor's Note The Allergy Immunotherapy Market is experiencing significant growth, driven by a global demand for long-term allergy management solutions. Stakeholders are focused on navigating new regulatory pathways and integrating innovative therapies into existing healthcare systems.

Therapy Area Industry Analysis Reports:-

Inflammatory Bowel Disease Treatment Market

<https://www.futuremarketinsights.com/reports/inflammatory-bowel-disease-treatment-market>

Intratumoral Cancer Therapies Market

<https://www.futuremarketinsights.com/reports/intratumoral-cancer-therapies-market>

Age Related Molecular Degeneration Market

<https://www.futuremarketinsights.com/reports/age-related-macular-degeneration-market>

Rahul Singh

Future Market Insights Inc.

+1 347-918-3531

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/837719991>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.